Sarepta set to report earnings as new CEO faces ELEVIDYS test
Sarepta Therapeutics is poised to release its second-quarter earnings, with investors keenly observing the performance of its gene therapy ELEVIDYS under new CEO Michael Severino. The company faces scrutiny over whether ELEVIDYS sales can stabilize after a recent decline and safety concerns, impacting market …